Back to Journals » Clinical Ophthalmology » Volume 4

Randomized controlled trial on the safety of intracameral cephalosporins in cataract surgery

Authors Lam P, Young AL, Cheng L, Tam, Lee V

Published 8 December 2010 Volume 2010:4 Pages 1499—1504


Review by Single anonymous peer review

Peer reviewer comments 2

Philip TH Lam, Alvin L Young, Lulu L Cheng, Patrick MK Tam, Vincent YW Lee
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong SAR, China

Objective: To compare the safety profiles of intracameral cephalosporins in cataract surgery.
Patients and methods: In this controlled trial, 129 patients were randomized to one of four groups to receive 1 mg of one of three cephalosporins – cefazolin, cefuroxime, or ceftazidime, or normal saline – given intracamerally during cataract surgery. Central endothelial cell density (ECD) and retinal center point thickness (CPT) were determined by specular microscopy and ocular coherence tomography, respectively, before and at 3 months after surgery.
Results: There were no statistical significant differences in the changes of ECD and CPT between eyes receiving intracameral cephalosporin and control.
Conclusion: The use of intracameral cefazolin, cefuroxime, or ceftazidime (1 mg in 0.1-mL solution) at the time of cataract surgery had no significant effect on ECD and CPT postoperatively.

Keywords: intracameral cephalosporin, endophthalmitis, phacoemulsification

Creative Commons License © 2010 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.